enough red, page-5

This is the response from tenbagger when asked on their current outlook on DMX...

Long term, Dolomatrix remains a BUY for the reasons outlined in the December report.

Short term, however, DMX is unlikely to outperform as the profit for the first half will underwhelm. The main reason for this is that the Chemsal acquisition was only finalised on November 30, so the net profit result will only include one month's contribution from Chemsal.

Looking to the full year result, the recent quarterly cashflows statement suggests revenue is tracking in line with management forecasts of $25-30m for the full year. With Chemsal, Enviropacific and Entech all contibuting to the second half of the year, the second half profit should be strong and, at this stage, we still expect the company will post a full year profit in line with our expectations.